FDA Premarket Safety Plan Is Not Cost-Effective Rx Development – PhRMA
Executive Summary
Safety requirements outlined in FDA's "Premarketing Risk Assessment" concept paper seem to run counter to Commissioner McClellan's emphasis on cost-effective drug development, the Pharmaceutical Research & Manufacturers of America said during a public workshop on risk management April 9
You may also be interested in...
Dose Ranging Study In Phase III Could Bolster Rx Safety Profile, Temple Says
Evaluating a range of doses in Phase III clinical trials could bolster the safety profile for an investigational new agent, FDA Office of Medical Policy Director Robert Temple, MD, said April 9
Dose Ranging Study In Phase III Could Bolster Rx Safety Profile, Temple Says
Evaluating a range of doses in Phase III clinical trials could bolster the safety profile for an investigational new agent, FDA Office of Medical Policy Director Robert Temple, MD, said April 9
Rx Name Risk Assessments Should Be Conducted By Manufacturers, FDA Says
Drug and biologic sponsors should conduct a risk assessment on the product's name, labeling and packaging to minimize medication errors, an FDA concept paper states